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Background: It is well-established that the etiology of type 2 diabetes differs between
individuals. Insulin resistance (IR) may develop in different tissues, but the severity of
IR may differ in key metabolic organs such as the liver and skeletal muscle. Recent
evidence suggests that these distinct tissue-specific IR phenotypes may also respond
differentially to dietary macronutrient composition with respect to improvements in
glucose metabolism.
Objective: The main objective of the PERSON study is to investigate the effects of an
optimal vs. suboptimal dietary macronutrient intervention according to tissue-specific IR
phenotype on glucose metabolism and other health outcomes.
Methods: In total, 240 overweight/obese (BMI 25 – 40 kg/m2) men and women (age 40
– 75 years) with either skeletal muscle insulin resistance (MIR) or liver insulin resistance
(LIR) will participate in a two-center, randomized, double-blind, parallel, 12-week dietary
intervention study. At screening, participants undergo a 7-point oral glucose tolerance
test (OGTT) to determine the hepatic insulin resistance index (HIRI) and muscle insulin
sensitivity index (MISI), classifying each participant as either “No MIR/LIR,” “MIR,” “LIR,”
or “combined MIR/LIR.” Individuals with MIR or LIR are randomized to follow one of
two isocaloric diets varying in macronutrient content and quality, that is hypothesized
to be either an optimal or suboptimal diet, depending on their tissue-specific IR
phenotype (MIR/LIR). Extensive measurements in a controlled laboratory setting as well
as phenotyping in daily life are performed before and after the intervention. The primary
study outcome is the difference in change in disposition index, which is the product of
insulin sensitivity and first-phase insulin secretion, between participants who received
their hypothesized optimal or suboptimal diet.
Discussion: The PERSON study is one of the first randomized clinical trials in the
field of precision nutrition to test effects of a more personalized dietary intervention
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based on IR phenotype. The results of the PERSON study will contribute knowledge
on the effectiveness of targeted nutritional strategies to the emerging field of precision
nutrition, and improve our understanding of the complex pathophysiology of whole body
and tissue-specific IR.
Clinical Trial Registration: https://clinicaltrials.gov/ct2/show/NCT03708419,
clinicaltrials.gov as NCT03708419.
Keywords: precision nutrition, personalized nutrition, insulin resistance, metabolic phenotype, glucose
homeostasis, obesity, dietary intervention study, randomized clinical trial
INTRODUCTION
The prevalence of overweight and relatedmetabolic disturbances,
including impaired glucose homeostasis, is rising at an
alarming rate, thereby increasing the risk for type 2 diabetes
mellitus (T2DM) and cardiovascular disease (CVD) (1). Dietary
modulation can effectively lower blood glucose levels and reduce
the risk of chronic metabolic diseases, independent of weight loss
(2, 3). Interestingly, there is great heterogeneity in individuals’
metabolic response to dietary interventions (4, 5). Part of this
heterogeneity may be attributed to differences in adherence, but
recent findings of large inter-individual variation in postprandial
responses to standardized meals indicate that individuals actually
respond differently to food (6, 7). This inter-individual variation
in response to food has complex underpinnings that include
biological (including genetic), environmental, and lifestyle
factors, and may partly explain the differential metabolic impact
of dietary interventions (4–9).
Whole-body insulin resistance (IR) reflects defective insulin
action in tissues such as skeletal muscle, liver, adipose tissue,
gut and brain, and is a major risk factor for T2DM and CVD.
IR can develop concurrently in different tissues, but the severity
of IR may vary between tissues (10, 11). Individuals may, for
example, have IR predominantly in the liver or skeletal muscle
(10). Liver insulin resistance (LIR) is manifested by impaired
insulin-mediated suppression of hepatic glucose production
(HGP), while muscle insulin resistance (MIR) is characterized
by decreased insulin-mediated glucose disposal (11). The gold-
standard method to quantify LIR and MIR is the two-step
hyperinsulinemic-euglycemic clamp (11). Tissue-specific IR can
also be modeled based on glucose and insulin responses during
an oral glucose tolerance test (OGTT), which has been validated
against the clamp technique (10, 12).
These tissue-specific IR phenotypes have previously been
linked to distinct metabolic profiles, representing different
etiologies toward T2DM and CVD (11, 13–15). More
specifically, greater disturbances in circulating lipidome (13)
and metabolome profiles (14) have been found in individuals
with more pronounced LIR as compared to individuals with
more pronounced MIR. Additionally, in individuals with
LIR, abdominal subcutaneous adipose tissue (scAT) has
been characterized by higher expression of genes related to
extracellular modeling, whilst MIR has been associated with
higher expression of genes related to inflammation in scAT, as
well as higher levels of circulating plasma markers of systemic
low-grade inflammation (16).
Recent findings indicate that these distinct metabolic
phenotypes may respond differently to dietary macronutrient
manipulation with regard to outcomes of glucose homeostasis,
ectopic fat deposition, and tissue-specific lipid metabolism
amongst others (15, 17). Indeed, a post-hoc analysis of the
CORDIOPREV-DIAB study has indicated that a low-fat, high-
complex carbohydrate diet may be particularly beneficial with
respect to improvement in glucose metabolism for individuals
with predominant LIR, while individuals with predominant
MIR seem to benefit more from a Mediterranean diet high in
monounsaturated fatty acids (MUFA) (18). Therefore, further
characterization of these IR phenotypes as well as studying
these metabolic phenotypes in relation to dietary intervention
outcomes may be a promising strategy to develop more
personalized dietary interventions. In addition, improvement of
glycemic control by more personalized dietary interventions may
enhance mood, self-control, and cognitive function (1, 19–21).
Such short-term benefits may in turn increase adherence to a
healthy diet.
Importantly, prospective randomized controlled trials with a
pre-specified hypothesis on differential metabolic responses to
diets based on (metabolic) phenotype are largely lacking in the
emerging field of precision nutrition. The PERSonalized glucose
Optimization through Nutritional intervention (PERSON) study
was designed to investigate the effects of an optimal compared
to a suboptimal dietary intervention according to tissue-specific
IR phenotype on glucose metabolism and other metabolic
health outcomes. This two-center, 12-week dietary intervention
study with a randomized, double-blind, parallel design, aims
to enroll a total of 240 individuals with either LIR or MIR.
Individuals are randomized to follow one of two diets that
are hypothesized to target one of the two tissue-specific
IR phenotypes.
Before and after the 12-week dietary intervention, individuals
are extensively phenotyped both in laboratory settings and
in daily life. The extensive phenotyping performed in this
unique clinical trial allows for a comprehensive study of both
the complex metabolic and lifestyle determinants of glucose
homeostasis, as well as the dietary intervention effects on
metabolic health and its metabolic underpinnings. In the present
article, we describe the study design and measurements in detail,
and present preliminary results of the screening population.
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METHODS
Study Design
The PERSON study is a two-center 12-week dietary intervention
study with a randomized, double-blind, parallel design, carried
out at Maastricht University Medical Center+ (MUMC+) and
Wageningen University & Research (WUR), the Netherlands
(Figure 1). The protocol was approved by the Medical Ethics
Committee of MUMC+ (NL63768.068.17) and registered
at ClinicalTrials.gov (identifier NCT03708419). The study is
conducted according to the principles of the Declaration of
Helsinki (revised version, 2013, Fortaleza, Brazil), and all subjects
provide written informed consent before the start of the study.
The primary study outcome is the difference in change in
disposition index, which is the product of insulin sensitivity
and first-phase insulin secretion, between participants who
received their hypothesized optimal or suboptimal diet.
Secondary outcome parameters include whole-body and tissue-
specific insulin sensitivity and glucose homeostasis, fasting and
postprandial metabolic profile, vascular health, fecal microbiota
composition and functionality, body fat distribution, ectopic fat
accumulation, adipose tissue morphology and gene expression,
skeletal muscle protein and gene expression, fasting immune
metabolism, cognitive performance, and perceived well-being.
Study Participants
From May 2018 onwards, subjects have been recruited via
a volunteer database, flyers, and advertisements in local and
online media. Inclusion criteria are age 40–75 years, body mass
index (BMI) 25–40 kg/m2, body weight stability for at least
3 months (no weight gain or loss >3 kg), and tissue-specific
IR, characterized as predominant LIR or MIR, as assessed by
a 7-point OGTT (see “Screening”). Exclusion criteria include
among others pre-diagnosis of T2DM, diseases or use of
medication that affect glucose and/or lipid metabolism, major
gastrointestinal diseases, history of major abdominal surgery,
uncontrolled hypertension, smoking, alcohol consumption
>14 units/wk, and >4 h/wk moderate-to-vigorous physical
activity (see Supplementary Table 1 for the extensive list of
exclusion criteria).
Screening
Eligibility is assessed during a screening visit. Subjects are asked
to refrain from alcohol and vigorous physical activity 24 h prior
to the visit and arrive in the morning after a>10 h overnight fast.
Body weight and height are measured in duplicate without shoes
and heavy clothing to the nearest 0.1 kg and 0.1 cm, respectively.
Waist and hip circumference are measured in duplicate to
the nearest 0.1 cm using a non-flexible measuring tape. Blood
pressure is measured in triplicate on the non-dominant arm
with an automated sphygmomanometer after a 5-min rest with
the subject in a supine position. The first measurement is used
to acclimatize the subject to the measurements, and therefore
omitted from the data.
Tissue-specific insulin resistance is assessed based on the
glucose and insulin responses during a 7-point OGTT. Subjects
ingest 200ml of a ready-to-use 75 g glucose solution (Novolab)
within 5min, and blood samples are collected from the
antecubital vein via an intravenous cannula under fasting
conditions (t = 0min) and after ingestion of the glucose drink (t
= 15, 30, 45, 60, 90, and 120min) for determination of plasma
glucose and insulin concentrations. Hepatic IR and muscle
insulin sensitivity are estimated using the calculations of Abdul-
Ghani and colleagues (10). We have recently optimized the MISI
calculator using the cubic spline method (12). The hepatic IR
index (HIRI) and muscle insulin sensitivity index (MISI) are
calculated according to the following formulas:
HIRI = glucose 0-30
[










mean during OGTT in pmol/L
]
In the formula for MISI, dG/dt is the rate of decay of plasma
glucose concentration (mmol/L) during the OGTT, calculated as
the slope of the least square fit to the decline in plasma glucose
concentration from peak to nadir (10).
Glucose curves that are flagged by the calculator, because
MISI calculation is not possible or possibly not biologically
meaningful due to either a peak at 120min, a “flat” curve, or non-
negligible rebound (12), are visually inspected for classification
of MIR and LIR. Both indices were developed and validated
against gold standard measurements of tissue-specific IR by a
hyperinsulinemic-euglycemic clamp (10, 12). To obtain study
groups that are predominant LIR or MIR, subjects are classified
as “No MIR/LIR,” “MIR,” “LIR,” or “combined MIR/LIR,” using
tertile cutoffs for MISI and HIRI. The lowest tertile of MISI
represents individuals with MIR, while the highest tertile of
HIRI represents individuals with LIR. The cutoffs for these
tertiles are based on values of a selected study population of
The Maastricht Study (DMS) (22), which resembles the target
population of the PERSON study. Since the prevalence of LIR
seems lower in the PERSON study as compared to DMS after
inclusion of n = 163 individuals, the median HIRI value in
the PERSON study population will be used for classification
of individuals that will be recruited for the remainder of
the study.
From the OGTT, incremental area under the curve (iAUC)
is calculated for both glucose and insulin using GraphPad
Prism software (version 5.04). Only values above the fasting
value are included in the iAUC. The homeostasis model
assessment of insulin resistance (HOMA-IR) is calculated as
(fasting glucose [mmol/L] × fasting insulin [mU/L])/22.5 (23).
HOMA of β-cell function (HOMA- β) is calculated as (20
× fasting insulin [mU/L])/(fasting glucose [mmol/L] – 3.5).
Matsuda index is defined as: [10,000 ÷ square root of [fasting
plasma glucose (mmol/l) × fasting insulin (pmol/l)] × [mean
glucose (mmol/l) x mean insulin (pmol/l)]], using glucose and
insulin values of time points 0, 30, 60, 90, and 120min (24).
Disposition index is calculated as: [Matsuda index ∗ (AUC30min
insulin/AUC30min glucose)], where AUC30min is the area
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FIGURE 1 | Study design of the PERSON study. Tissue-specific insulin resistance (MIR, muscle insulin resistance; LIR, liver insulin resistance) is assessed at screening
using a 7-point oral glucose tolerance test and eligible participants with MIR or LIR are randomized to follow either their hypothesized optimal (dark purple) or
suboptimal (light purple) diet for 12 weeks. Before and after the intervention, participants are extensively phenotyped during a “characterization week” in a controlled
laboratory setting as well as in daily life. BMI, body mass index; MUFA, monounsaturated fatty acid.
under the curve between baseline and 30min of the OGTT
for insulin (pmol/l) and glucose (mmol/l) as calculated using
the trapezoidal method, respectively. Glucose status is defined
according to WHO criteria (25): normal glucose tolerance
(NGT), fasting glucose <5.6 mmol/L and 120-min glucose <7.8
mmol/L; impaired fasting glucose (IFG), fasting glucose 5.6
– 6.9 mmol/L and 120-min glucose <7.8 mmol/L; impaired
glucose tolerance (IGT), fasting glucose <5.6 mmol/L and 120-
min glucose 7.8 – 11.0 mmol/L; combined IFG/IGT, fasting
glucose 5.6 – 6.9 mmol/L and 120-min glucose 7.8-11.0 mmol/L;
T2DM, fasting glucose ≥7.0 mmol/L and/or 120-min glucose
≥11.1 mmol/L.
Hb and the parameters of hepatic and renal function
alanine aminotransferase (ALT), aspartate aminotransferase
(AST), and creatinine are determined in fasting blood samples
by the hospital laboratories of MUMC+ and Ziekenhuis
Gelderse Vallei, Ede, the Netherlands. Habitual dietary intake
is estimated by a validated 163-item semiquantitative food
frequency questionnaire (FFQ) (26). Dietary misreporting is
evaluated by Goldberg’s method, using the ratio of daily
energy intake (EI) to estimated basal metabolic rate (BMR)
(27, 28). Energy under- (EI/BMR < 0.87) and overreporters
(EI/BMR > 2.75) are excluded from data analyses. Data
on demographics, medical history, family history of DM
(≥1 first-degree relative with DM), medication use and
lifestyle are collected by questionnaire. Education level is
categorized into low (no education, primary education, lower
or preparatory vocational education, lower general secondary
education), medium (intermediate vocational education, higher
general senior secondary education or pre-university secondary
education) and high (higher vocational education, university).
Perceived chronic stress is assessed with the Long-term
Difficulties Inventory (29) andmental well-being with the RAND
36-Item Short Form Health Survey (RAND-36) (30) and the
Social Production Function Instrument for the Level of Well-
being (31).
Randomization Procedure
Eligible subjects are randomly allocated to either their
hypothesized optimal or suboptimal diet by an independent
analyst using center-specific minimization (32, 33) with
randomization factors of 1.0 for the LIR/MIR phenotype, and
0.8 for age and sex, and a base probability of 0.7 by means of
biased-coin (34). Both researchers and participants are blinded
to the participants’ metabolic phenotype, and thus blinded to
whether participants are allocated to their hypothesized optimal
or suboptimal diet. Participants start the study within 3 months
of the screening visit.
Dietary Intervention
The hypothesized optimal diet forMIR is amoderate-fat diet high
in MUFA (HMUFA) with a targeted macronutrient composition
of 38% of energy from fat (20% MUFA, 8% PUFA, 8% SFA),
48% of energy from carbohydrates (CHO) (30% polysaccharides;
3 g/MJ fiber), and 14% of energy from protein (Table 1). The
hypothesized optimal diet for LIR is low in fat, and high in
protein (LFHP) and fiber. Energy from CHO is similar between
diets. The targeted macronutrient composition of the LFHP diet
is composed of 28% of energy from fat (10% MUFA, 8% PUFA,
8% SFA), 48% of energy from CHO (30% polysaccharides; >4
g/MJ fiber), and 24% of energy from protein (Table 1).
The dietary intervention strategy is based on intensive dietary
counseling and provision of key products. Before the start
of the intervention, a short dietary history is performed to
assess the participants’ dietary habits and preferences. This
information is used to individualize the dietary plan and
counseling accordingly. Participants are assigned to one of
eight energy groups ranging from 6 to 13 MJ/d according
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TABLE 1 | Targeted nutrient composition of the HMUFA and LFHP diet.
HMUFA LFHP
Fat (en%) 38 28
Monounsaturated fat 20 10
Polyunsaturated fat 8 8
Saturated fat 8 8
Protein (en%) 14 24
Animal-based, % of total protein 45 60
Plant-based, % of total protein 55 40
Carbohydrates (en%) 42 42
Mono- and disaccharides 12 12
Polysaccharides 30 30
Fiber, g/MJ 3 >4
Alcohol <3 <3
En%, energy percentage of total energy intake; MJ, megajoule.
to their estimated individual energy requirement, which is
calculated by averaging self-reported energy intake from the
FFQ with the product of the predicted BMR, as calculated
with Schofield equations (35), and self-reported physical
activity level.
At the start of the intervention period, participants receive
verbal and written instructions on their dietary plan, which lists
both types and quantities of foods that they are required to
consume daily or weekly in order to meet the targeted nutrient
composition of the assigned diet. The instructions include
guidance on what types of foods to choose and avoid within all
food groups (e.g., what grain products are [not] allowed; what
type and cut of meat or poultry is [not] allowed). Intake of so-
called free-food items (e.g., from caloric sweeteners, sweets, sweet
spreads, cookies, fruit juice, sugar-sweetened and/or alcoholic
beverages) is restricted to 5–10% of energy intake in both diets.
The individual dietary plans include a number of “points” per day
that have to be “spent” on such foods.
Key products that largely distinguish the two diets with
regards to macronutrient composition are provided in pre-
measured amounts. For the HMUFA diet, key products include
olive oil, olives, olive tapenade, and low-fat margarine with olive
oil. Key products for the LFHP diet include low-fat yogurt and
quark, reduced-fat cheese, very low-fat spread, pumpkin seeds,
baking margarine with olive oil, and a dietary fiber supplement
(2 g β-glucan per 6 g, PromOat R©, DSM Nutritional Products,
Basel, Switzerland) providing 6–12 g of additional fiber per day.
Participants are instructed to finish a certain amount of every
provided product each day. Apart from the fiber supplement,
all products are commercially available. Alcohol consumption is
restricted to ≤1 glass/day, in agreement with the current Dutch
dietary guidelines (36).
Throughout the intervention period, participants visit the
research facilities every week for a 15- to 30-min individual
dietary counseling session with a dietitian or research nutritionist
to monitor diet adherence, body weight, and adverse events
using a semi-structured interview. These sessions are supported
by advice via e-mail or telephone if needed. To be able to
assess the effects of the dietary intervention on metabolic health
parameters, independent of changes in body weight, we aim to
keep participants on a stable body weight throughout the study.
In case of weight loss or gain, participants are reassigned to a
higher or lower energy group to prevent further weight change.
To promote overall diet adherence, participants are allowed
to deviate from their dietary plan on three individual days
throughout week 2–10 of the intervention period. Participants
are asked to keep a food record (FR) on these days.
During the COVID-19 restrictions, the weekly on-site visits
are replaced by telephone or video-call consultations, key
products are home-delivered by courier, and participants weigh
themselves at home.
Dietary compliance is assessed by three unannounced 1-day
FR with the mobile app “Traqq” (37) on 2 non-consecutive
weekdays and 1 weekend day. Participants are provided with
written and face-to-face instructions on how to record dietary
intake. Participants that do not have a smartphone complete
the FRs on paper, which are later entered into the app by
the researcher.
Measurements
In the week before start of the intervention and in the last
week of the 12-week intervention, participants are extensively
phenotyped during a “characterization week” (Figure 2). This
week includes three or four (depending on study center and
participation in additional subgroup measurements) clinical test
days and three at-home days. Participants wear a continuous
glucose monitor (CGM) and activity monitor throughout the
characterization week. During the clinical test days, participants
undergo extensive laboratory testing, which includes challenge
tests, body composition analysis, vascular measurements, tissue
biopsies, a cognitive test, and questionnaires. During the at-home
days, participants record dietary intake and feelings of well-being,
consume various standardized meals, and collect feces and urine.
An overview of all measurements can be found in Figures 2, 3
and are described in more detail below.
On the clinical test days, participants are instructed to travel
to the facility by car or public transport. The day prior to and
during the characterization weeks, participants are requested to
refrain from alcohol and vigorous physical activity. In the week
before the baseline characterization week, participants record
their dietary intake for three random days (2 week days and 1
weekend day) using the mobile app “Traqq” (37).
Laboratory Challenge Tests
A 7-point OGTT is performed according to the same procedures
used at screening (see “Screening”) (Figures 3, 4). Participants
consume a standardized low-fat macaroni meal (30% of energy
intake [en%] fat, 49 en% CHO, 21 en% protein; 1,560–2,460 kJ,
depending on energy group) the evening before the OGTT, after
which they remain fasted until the OGTT. The macaroni meal
is prepared in the university kitchen. A fasting blood sample is
drawn for determination of glycated hemoglobin (HbA1c) by the
hospital laboratories ofMUMC+ and Ziekenhuis Gelderse Vallei,
Ede, the Netherlands.
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FIGURE 2 | Graphical overview of the pre- and post-intervention characterization week. The characterization week contains multiple clinical test days, during which
participants are extensively phenotyped. In addition, blood glucose and physical activity are continuously monitored. At home, participants record their dietary intake
and feelings of well-being, collect a fecal sample and 24-h urine, and consume a standardized breakfast on day 4, and on day 5, participants have a full day of
standardized meals and snacks, including the standardized breakfast. In a subgroup of the study population, additional measurements are performed. DXA,
dual-energy X-ray absorptiometry; MRI, magnetic resonance imaging; 1H-MRS, proton magnetic resonance spectroscopy; AGEs, advanced glycation endproducts;
CAR, carotid artery reactivity; OGTT, oral glucose tolerance test; GI, gastrointestinal; scAT, subcutaneous adipose tissue; SM, skeletal muscle.
On a separate clinical test day, at least 4 days after the OGTT, a
high-fat mixed-meal (HFMM) challenge test is performed after a
12-h overnight fast (Figures 3, 4). Participants again consume the
standardized low-fat macaroni meal the evening before the test.
The liquid HFMM (350 g containing 2.8 MJ, 49 g [64 en%] fat,
48 g [29 en%] carbohydrate, 12 g [7 en%] protein) is prepared in
the university kitchen using whipped cream ice cream, whipped
cream, full-fat milk, and sugar (Supplementary Table 2). An
intravenous cannula is inserted in the antecubital vein for blood
sampling. At least 30min following insertion of the catheter,
a fasting blood sample is drawn (t = 0min). Subsequently,
participants are asked to consume the liquid HFMM within
5min and postprandial blood samples are drawn at t = 30,
60, 90, 120, 180, and 240min for determination of glucose,
insulin, free fatty acids (FFA), triacylglycerol (TAG), glucagon-
like peptide 1 (GLP-1), and peptide YY (PYY) (Figure 4). Total
cholesterol andHDL cholesterol are determined in fasting serum.
Extensive plasma metabolite profiling is performed in samples
from T = 0, 30, 60, 120, and 240min by high-throughput nuclear
magnetic resonance (NMR) metabolomics (Nightingale Health
Ltd., Helsinki, Finland) (38). Buffy coat is collected from fasting
blood for later DNA isolation and genotyping. At each blood
drawing, participants rate their hunger, fullness, satiety, thirst,
and desire to eat on a 100-mm Visual Analog Scale (VAS),
anchored at the extremes “not at all” to “extremely.”
Cardiovascular Markers
Blood pressure is assessed according to the same procedures used
at screening. In a subgroup of participants, vascular function
is assessed by measuring carotid artery reactivity (CAR) to a
cold pressor test (CPT) (39). After 10min of rest in supine
position, the participant’s left hand is submerged in a bucket of
icy water (≤4◦C) for 3min. The diameter of the left common
carotid artery is monitored during a 1-min baseline assessment
and continuously during the 3-min CPT using ultrasound
(Terason uSmart 3300, Burlington, MA, USA). Wall-tracking
and edge-detecting software is used to calculate the diameter
after completion of the test. To confirm sympathetic stimulation,
blood pressure is measured after the supine rest, 1-min and 2-
min after the start of the CPT, and directly after completion
of the CPT (Omron M6 Comfort, Omron healthcare Co., Ltd.,
Kyoto, Japan).
In a subgroup, skin accumulation of advanced glycation end-
products (AGE) is measured by skin autofluorescence (AF) using
the automated AGE reader (DiagnOptics Technologies B.V.,
Groningen, the Netherlands). Skin AF is measured at three
slightly different places on the volar side of the dominant arm,
avoiding impurities of the skin such as scars and birthmarks.
Participants are instructed to not apply any creams, lotions, or
sunscreen on their arms on the day of the measurement.
Body Composition, Fat Distribution, and Ectopic Fat
Deposition
Body weight is measured in underwear, and waist and hip
circumference are measured according to the procedures
described earlier (see “Screening”). Whole-body and regional fat
mass, fat percentage, lean body mass, and bone mineral density
are assessed using dual-energy X-ray absorptiometry (DXA),
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FIGURE 3 | Overview of all measurements performed within the PERSON study. *Performed in a subgroup of the study population. SCR, screening visit; CW,
characterization week; DIW, dietary intervention week.
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FIGURE 4 | Graphical overview of the oral glucose tolerance test and the
high-fat mixed-meal (HFMM) test that are performed during the pre- and
post-intervention characterization week. Participants are instructed to drink
the glucose drink or HFMM within 5min, and fasting and postprandial blood
samples are drawn at the indicated timepoints for determination of the
indicated metabolites. CHO, carbohydrates; HbA1c, hemoglobin A1c; FFA,
free fatty acids; TAG, triglycerides; GLP-1, glucagon-like peptide 1; PYY,
peptide YY; NMR, nuclear magnetic resonance; HDL, high-density lipoprotein;
SCFA, short-chain fatty acids; PBMCs, peripheral blood mononuclear cells.
while participants are fasted for ≥2 h (MUMC+, Discovery A,
Hologic; WUR, Lunar Prodigy, GE Healthcare) (Figure 3).
At MUMC+, a whole-body scan is made after a ≥2 h
fast with a 3T magnetic resonance imaging (MRI) scanner
(3T MAGNETOM Prisma fit, Siemens Healthcare), using
a radiofrequency transmit/receive body coil at Scannexus,
Maastricht, the Netherlands. Analyses are performed using
a computational modeling method [AMRA Medical AB,
Linköping, Sweden (40)] for quantification of abdominal
subcutaneous adipose tissue (ASAT), visceral adipose tissue
(VAT), thigh muscle volume, intrahepatic lipid content (IHL),
and muscle fat infiltration (MFI) in the anterior thighs
(Figure 3).
At WUR, IHL and abdominal fat distribution are assessed
with proton magnetic resonance spectroscopy (1H-MRS) and
MRI, respectively, on a 3T whole-body scanner (Siemens,
Munich, Germany; Philips Healthcare, Best, the Netherlands
from November 2020 onwards). MRI measurements are
performed after a ≥2 h fast at hospital Gelderse Vallei,
Ede, the Netherlands. Spectra for determination of IHL are
obtained from a 30 × 30 × 20mm voxel placed in the
right lobe of the liver, avoiding blood vessels and bile
ducts. Participants are instructed to hold their breath when
spectra are acquired to reduce respiratory motion artifacts.
Spectra are post-processed and analyzed using the AMARES
algorithm in jMRUI software. Abdominal fat distribution is
evaluated as subcutaneous (ASAT) and visceral adipose tissue
(VAT) areas in the abdomen, which are quantified in singles-
slice axial T1-weighted spin echo transverse images at the
inter-vertebral space L3-L4 using the semi-automatic software
program HippoFatTM (41).
Microbiota Composition and Functionality
During one of the at-home days in the characterization week,
participants collect fecal samples (Figures 2, 3). The samples
are stored in the participants’ home freezer for maximal 72 h
before the visit to the research facilities. Participants rate stool
consistency of the sample using the Bristol stool scale (42). Fecal
microbiota composition is determined by 16S rRNA sequencing
as described elsewhere (43).
During the HFMM challenge test, fasting and postprandial
blood samples are collected for determination of plasma
concentrations of GLP-1 and PYY (Figure 3). Fecal
concentrations and fasting plasma levels of gut microbiota-
derived short-chain fatty acids (SCFA) acetate, propionate and
butyrate are determined using optimized LC-MS protocols (44).
Data on self-reported gastrointestinal health are collected
by a questionnaire based on the Rome III criteria (45). The
questionnaire includes questions on presence of gastrointestinal
complaints (i.e., abdominal pain, obstipation, bloating),
defecation frequency, and stool consistency (Figure 3).
In addition, oral samples are collected for microbiological
and metabolite analyses. Participants are asked to rinse the oral
cavity thoroughly for 30 s with 10ml of sterile 0.9% saline and
expectorate the rinse in a tube. The tube is kept on ice, vortexed
and the rinse is aliquoted, snap-frozen in liquid nitrogen and
stored at −80 ◦C for later analysis. Participants are instructed to
refrain from oral hygiene in the morning of the sampling day.
The composition of the oral microbiome is determined by 16S
rRNA sequencing (46).
Deep Laboratory Phenotyping
Abdominal Subcutaneous Adipose Tissue Biopsy
On the morning of the HFMM, an abdominal SAT biopsy
is collected 6–10 cm lateral from the umbilicus under local
anesthesia (1% lidocaine) by needle biopsy. The samples are
washed with saline to remove blood clots. A portion of tissue is
fixed overnight at 4◦C in 4% paraformaldehyde and embedded
in paraffin for histological sections to determine adipocyte
morphology. In a subgroup of participants, at baseline only,
∼0.7 g of fresh AT is used for fluorescence activated cell sorting
(FACS) analysis. In short, the stromal vascular fraction is
isolated from the AT and stained with a cocktail of antibodies
for flow cytometry for identification of immune cells (47).
The remaining tissue is snap-frozen in liquid nitrogen and
stored at −80 ◦C for later analyses of targeted gene and
protein expression.
Skeletal Muscle Biopsy
In a random subgroup of participants at MUMC+ (n = 60
in total; n = 15 per intervention group), a skeletal muscle
(SM) biopsy is collected and a two-step hyperinsulinemic-
euglycemic clamp is performed on a separate clinical test day
at the end of the characterization week (Figure 3). The skeletal
muscle biopsy is taken from the m. vastus lateralis under local
anesthesia using the Bergström biopsy needle method (48). After
removal of blood and fat tissue, a portion of the biopsy is
snap-frozen in melting isopentane and stored at −80 ◦C for
biochemical analyses. The remaining tissue is snap-frozen in
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liquid nitrogen and stored at −80 ◦C for later gene and protein
expression analyses.
Two-Step Hyperinsulinemic-Euglycemic Clamp
After the SM biopsy, whole-body and tissue-specific insulin
sensitivity are assessed by the gold standard two-step
hyperinsulinemic-euglycemic clamp (49). At t = −120min,
primed D-[6.6-2H2] glucose tracer is started and infused
continuously at 0.04 mg/kg/min, to allow calculations of rates
of endogenous glucose production (EGP), glucose appearance
(Ra), and glucose disposal at basal conditions. At t = 0, a low
primed constant co-infusion of insulin at 10 mU/m2/min is
started for 3 h for determination of hepatic insulin sensitivity.
At t = 180min, the primed constant infusion of insulin is
increased to 40 mU/m2/min for 2.5 h to inhibit EGP and
measure muscle insulin sensitivity. Arterialized blood is
frequently sampled from the superficial dorsal hand vein
during the insulin infusion to measure glucose concentrations,
which are maintained at ∼5.0 mmol/L by a co-infusion of 20%
glucose at variable rate (GIR). Substrate utilization is measured
for 30min during the basal, low insulin, and high insulin
infusion using indirect calorimetry by ventilated hood (Omnical,
Maastricht Instruments, Maastricht). Resting metabolic rate
(RMR), fat and carbohydrate oxidation are calculated according
to the equations of Weir and Frayn (50, 51). The clamp is
performed after an overnight (≥12 h) fast and participants
consume the standardized macaroni meal the evening before
the clamp.
Fasting Immune Metabolism
At WUR only, circulating peripheral blood mononuclear cells
(PBMCs) are isolated from fasted blood samples collected at
the HFMM test (Figure 3). In addition, in a random subgroup
(n ∼ 200), PBMCs are also isolated from fasted blood samples
collected at screening. PBMCs are isolated by density gradient
isolation using CPT tubes (BD vacutainer, cat. no. 362753).
Monocytes are subsequently obtained by MACS (magnetic
activated cell sorting) positive selection using CD14 MicroBeads
(Miltenyi Biotec, cat no. 130-050-201). Part of the monocytes
are exposed overnight (24 h) to the inflammatory stimuli
lipopolysaccharide (LPS) (10 ng/mL, sigma, cat. no L6529) and
P3C (10 ug/mL, EMC collections, cat. no. L2000). Functional
properties of monocytes are determined after treatment by
measuring the release of cytokines including IL-6, IL-1b and
CXCL8 (R&D DuoSet ELISA, cat. no. DY206; DY201; DY208).
The metabolic potential of monocytes is measured in real-time
experiments (inflammatory cell activation test and glycolytic
stress test) using the Seahorse apparatus (Agilent Technologies)
in screening samples only.
24-h Urine Collection
Participants collect 24-h urine in 2-3 liter containers containing
5 ml/L of 4mM hydrochloric acid (HCl). Urine collection starts
after the first voiding on the morning of the home-day with
only standardized meals and finishes 24 h later on the morning
of the HFMM. Participants are asked to store the containers in
a cool place, preferably a refrigerator, and bring the containers
to the facilities on the day of the HFMM. The urine of each
participant is mixed, weighted, aliquoted, and stored at −80 ◦C
for later analysis.
Measurements in Daily Life and At-Home Days
Continuous Glucose Monitoring
At the start of the characterization week, a CGM (Medtronic
iPro2 with Enlite sensor) is placed lateral to the umbilicus for
6 days of continuous interstitial fluid glucose measurements
(Figure 2). The CGM data are calibrated according to the
manufacturer’s instructions with four daily capillary glucose
self-measurements using a blood glucose meter (Contour XT,
Ascensia Diabetes Care).
To assess glycemic variability and glycemic responses to
standardized meals, on one of the home-days, participants
consume a standardized breakfast, and on another home-
day, participants have a full day of standardized meals
and snacks, including the standardized breakfast (Figure 2;
Supplementary Tables 3, 4). Participants are instructed to
consume the meals according to standardized instructions
including time frames, to fast for 2 h after the breakfast, and to
only drink water alongside the standardized meals.
Physical Activity Assessment
Physical activity is continuously monitored for ∼14 days during
both the characterization weeks and ∼7 days in free-living
conditions–either starting with the characterization week at
baseline, or ending with the characterization week in week 12
(Figure 2)–using a triaxial accelerometer (activPAL3TM micro,
PAL Technologies Ltd., Glasgow, Scotland, UK) attached to the
middle of the right thigh. Participants keep a diary to record the
times they go to sleep and wake up while wearing the monitor.
Sedentary and physical activity parameters are quantified with a
modified version of the script of Winkler et al. (52), using the
sleeping and waking times as input.
Dietary Intake, Hunger, Mood, and Sleepiness
During the 3 at-home days, participants record their dietary
intake including consumption of the standardized meals using
the mobile app “Traqq” (37). In addition, participants are asked
to report on hunger, mood, and sleepiness every 2 h from 8:00
to 22:00 h (Figure 2). Hunger is rated on an 11-point Likert
scale ranging from “not hungry” to “very hungry.” Self-reported
mood is assessed with an adapted form of the Multidimensional
Mood Questionnaire (MDMQ) (53). The 7-point scale consists
of six bipolar items to assess the three basic dimensions of
mood valence, calmness, and energetic arousal: tired/awake,
satisfied/dissatisfied, agitated/calm, full of energy/without
energy, unwell/well, and relaxed/tense. Sleepiness is rated on the
9-point Karolinska Sleepiness Scale, with labels ranging from
“extremely alert” to “very sleepy, great effort keeping awake,
fighting sleep” (54, 55).
Cognitive Performance
Cognitive performance is assessed in the domains of executive
function, memory, and attention & psychomotor speed using
the Cambridge Neuropsychological Test Automated Battery
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(CANTAB) (56). Executive function is evaluated with the
multitasking test and spatial span test; memory with the delayed
matching to sample test and paired associates learning test;
and attention and psychomotor speed is assessed with the
motor screening task and reaction time task. Each test is
preceded by standardized instructions and a practice round
for familiarization. Participants consume a standardized brunch
containing of bread with cheese and/or ham and a caffeine-free
drink before performing the test battery.
Self-Reported Food Preferences, Eating Rate, Sleep,
Well-Being, and Physical (In)-activity
After the CANTAB, participants complete the computer-based
Macronutrient and Taste Preference Ranking Task (MTPRT) for
assessment of food preferences (57). The task assesses liking and
ranking for 32 food products that are categorized as high in
carbohydrates, high in fat, high in protein, or low-calorie, as well
as either sweet or savory. Furthermore, participants rate their
eating rate in comparison to others on a 5-point Likert scale with
labels ranging from “very slow” to “very fast” (Figure 3).
In addition, during one of the clinical test days, participants
provide information on general well-being, sleep characteristics,
and physical (in)activity by questionnaire (Figure 3). Mental
well-being is assessed using the RAND-36 (30) and perceived
stress is measured with the 10-item Perceived Stress Scale (PSS-
10) (58). Physical and mental fatigue are assessed using the 14-
item Chalder fatigue scale (59). Sleep quality is assessed with the
10-item Pittsburgh Sleep Quality Index (60) and sleep duration
and chronotype are derived from the Munich ChronoType
Questionnaire (61). Daytime sleepiness is assessed with the 8-
item Epworth Sleepiness scale (62) (Figure 3).
Self-reported habitual physical activity and sedentary behavior
are assessed using the Baecke questionnaire (63) and the Activity
Questionnaire for Adults and Adolescents (AQuAA) subscale
“sedentary leisure time activities” (64), respectively. In addition,
physical activity self-efficacy is measured with 5 items from
a health specific self-efficacy scale (65) and physical inactivity
temptations are assessed using the 5-item subscale “competing
demands” from the Temptation to not Exercise Scale (66),
extended with the item “How tempted are you not to exercise and
be sedentary while being on a business trip?”.
Biochemical Analyses of Blood Samples and
Biobanking
A wide range of biological samples are collected in the present
study, including blood plasma and serum, SAT, SM tissue, feces,
urine, saliva, and PBMCs. EDTA (Becton Dickinson, Eysins,
Switzerland) tubes are centrifuged at 1,200 g, 4◦C for 10min and
plasma is aliquoted subsequently. Serum tubes are left at room
temperature for at least 30min to allow clotting after sampling
and centrifuged at 1,200 g, 20◦C for 10min before aliquoting of
serum. All biological samples are snap-frozen in liquid nitrogen
and stored at −80◦C until analysis. Samples from both centers
are analyzed at central laboratories. Plasma glucose, insulin, and
FFA are measured on a Cobas Pentra C400 using ABX Pentra
Glucose HK CP reagens (Horiba ABX Diagnostics, Montpellier,
France), ELISA (Meso Scale Discovery, Gaithersburg, USA), and
NEFA HR (2) reagens (2) (Wako chemicals, Neuss, Germany),
respectively. Serum TAG, total cholesterol, and HDL cholesterol
are measured on a Cobas Pentra C400 using ABX Pentra
Triglycerides HK CP reagens, ABX Pentra Cholesterol CP
reagens, and ABX Pentra HDL Direct, respectively. During the
HFMM challenge test, fasting and postprandial blood samples
are collected in EDTA tubes and aprotinin tubes containing
dipeptidyl peptidase-IV inhibitor (Milipore Merck, Billerica,
MA, USA) for determination of plasma GLP-1 and PYY,
respectively. Total GLP-1 immunoreactivity is assessed using an
antiserum that reacts equally with intact GLP-1 and the primary
(N-terminally truncated) metabolite as previously described
(67). PYY concentrations are determined with a commercially
available radioimmunoassay for Human PYY (3-36) (Millipore
Corporation, MA, USA).
Data Management
Data are collected on paper case report forms (CRF) and are
entered in an electronic CRF designed for the study, using the
web-based data capturing platform Caster EDC (68) that is
compliant with good clinical practice (GCP) requirements. All
relevant raw and processed data (e.g., from blood analyses, DXA
scan) are also added to the eCRF in Castor EDC. Data entered
in the eCRF are checked against the paper CRF by a study team
member that did not enter the data. Data are collected and stored
according to the FAIR (Findability, Accessibility, Interoperability,
and Reusability) principles (69). A central datamanagermonitors
data entry of both centers, performs data cleaning, and ensures
that inaccurate or missing data are addressed.
Sample Size Calculation
Based on previous data, we expect a greater improvement in
disposition index in participants receiving their hypothesized
optimal diet compared to those receiving their hypothesized
suboptimal diet (10). Data from the previously published
DiOGenes study (18) as well as the CORDIOPREV-DIAB Study
(18) were used to calculate an average standardized effect size
from the difference in outcome values between the optimal and
suboptimal diets in those studies. For DiOGenes, the low vs.
high GI diets during the weight regain period were used and
for CORDIOPREV the Mediterranean vs. low fat-high complex
carbohydrate diets were used, in interaction with either MIR
or LIR. With a power of 90%, two-sided alpha of 5% and a
standardized effect size of 0.46, a total sample size of 202 was
calculated using the statistical analysis software R. Taking into
account a drop-out rate of 15%, 240 subjects will be included.
Statistical Analyses
In this paper, preliminary screening data from May 2018 to
March 2020 are included. Baseline characteristics were compared
between the four IR phenotypes (No MIR/LIR, MIR, LIR,
combined MIR/LIR), using one-way ANOVA with Bonferroni
post-hoc pairwise comparisons for numerical data (mean ±
SD), and using Fisher’s exact test for categorical data (%).
Parameters of glucose homeostasis from the OGTT and dietary
intake data from the FFQ were log-transformed due to non-
normality, and differences between the IR phenotypes were tested
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using ANCOVA with adjustment for sex and Bonferroni post-
hoc pairwise comparisons. Statistical analyses were performed
in SPSS (version 25.0). Differences in glucose and insulin
responses following the OGTT between the IR phenotypes
were tested using linear mixed-effects models (LMM) with
Bonferroni post-hoc pairwise comparisons. The time courses
of glucose and insulin were modeled with third-order (cubic)
orthogonal polynomials. The effect of IR phenotype on all
time terms and sex were included as fixed effects with
participant random effects on all time terms. The adequacy of
the higher order polynomials was assessed with a likelihood-
ratio test between nested models. The covariance matrix of
the residuals was modeled as an unstructured matrix and
model parameters were estimated using maximum likelihood
estimation in all models. Estimated marginal means (EMM)
with the degrees of freedom and corresponding p-values were
estimated using Satterthwaite’s method. All mixed-effects models
were implemented using the “lmer” function of the lme4 package
and EMMs were computed using the emmeans package in
R (version 3.3.3, The R foundation for Statistical Computing,
http://www.r-project.org/).
RESULTS
Between May 2018 and March 2020, 632 individuals were
enrolled, of whom 565 were fully screened for eligibility
(Figure 5). In total, 40.2% of fully screened individuals were
classified as NoMIR/LIR, 21.4% asMIR, 10.8% as LIR, and 27.6%
as combinedMIR/LIR. Here, we present the characteristics of the
study participants that have thus far been screened in the present
ongoing clinical trial.
Baseline Characteristics
Baseline characteristics of all participants that completed
screening are reported according to IR phenotype in Table 2.
Mean age of the four groups (60 – 62 years) was comparable.
The proportion of women in the total study population was
59% and was higher in the MIR group (69%) compared to
the other groups, but only statistically significantly different
from the combined MIR/LIR group. Individuals with combined
MIR/LIR had higher BMI, waist circumference, waist-to-hip
ratio, systolic and diastolic blood pressure, ALT levels, and use of
antihypertensive medication compared to the NoMIR/LIR,MIR,
and LIR groups. Anthropometric and clinical characteristics were
similar between the MIR and LIR group. IFG was most prevalent
in the LIR group (11.5%), while IGT was most prevalent in the
MIR group (18.2%) and the combined MIR/LIR group (16.7%).
The prevalence of newly diagnosed T2DM was 6.6%, 8.3%,
0.0%, and 10.9% in the No MIR/LIR, MIR, LIR, and combined
MIR/LIR group, respectively.
Glucose Homeostasis
By definition, both plasma glucose and insulin curves throughout
the OGTT differed between the IR groups (p < 0.001 for both;
Figure 6). Throughout the first 30min of the OGTT, plasma
glucose concentrations were higher in the LIR group compared
to the MIR group (Figure 6A). Plasma insulin concentrations
FIGURE 5 | Flowchart of participant enrollment and eligibility from March 2018
to March 2020.
were higher in the LIR group compared to the MIR group at
timepoints 15 – 60min, whereas at 120min, insulin was lower in
LIR compared to MIR (Figure 6D). The iAUCs of both glucose
and insulin were lowest in the No MIR/LIR group, highest in
the combined MIR/LIR group, and comparable between the
MIR and LIR group (overall p < 0.001; Figures 6C,F), as were
HOMA-IR (overall p < 0.001; Figure 7A) and HOMA-β (p <
0.001; Figure 7B). Similarly, Matsuda index was highest in the
No MIR/LIR group, lowest in the combined MIR/LIR group,
and comparable between the MIR and LIR group (overall p <
0.001; Figure 7C). Disposition index was higher in the LIR group
compared to the other groups (overall p = 0.002; Figure 7D).
Furthermore, by definition, MISI was lowest in the combined
MIR/LIR and the MIR group (overall p < 0.001; Figure 7E)
and HIRI was highest in the combined MIR/LIR and LIR group
(overall p < 0.001; Figure 7F). All analyses were adjusted for
sex. Values of these glucose homeostasis parameters derived from
OGTT are reported in Supplementary Table 5.
Habitual Dietary Intake
FFQ data were available from 549 participants. After exclusion
of data from 84 and 4 individuals due to energy under- and
overreporting, respectively, data from 461 participants were
included in the analyses. The proportion of misreporters did
not differ between the IR phenotypes (p = 0.411). Energy
intake tended to be lower in the MIR group compared to the
other groups when adjusted for sex (Table 3; p = 0.062). Intake
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TABLE 2 | Characteristics of screened participants according to insulin resistance phenotype.
No MIR/LIR MIR LIR Combined MIR/LIR P-value
(n = 227) (n = 121) (n = 61) (n = 156)
Age (years) 61 ± 9 60 ± 9 61 ± 8 62 ± 8 0.627
Women (%) 59.9 69.4 54.1 52.6† 0.031
Weight (kg) 86.6 ± 13.1 86.0 ± 11.2 86.4 ± 11.8 94.0 ± 14.7§†‡ <0.001
BMI (kg/m2 ) 29.2 ± 3.3 29.8 ± 3.1 29.6 ± 3.2 32.2 ± 4.1§†‡ <0.001
Waist circumference (cm) 98.5 ± 10.6 100.4 ± 9.5 99.9 ± 9.5 106.3 ± 11.0§†‡ <0.001
Waist-to-hip ratio 0.91 ± 0.09 0.92 ± 0.08 0.94 ± 0.09 0.95 ± 0.09§† <0.001
SBP (mmHg) 132 ± 17 132 ± 13 132 ± 16 137 ± 16§ 0.015
DBP (mmHg) 80 ± 11 80 ± 10 80 ± 11 85 ± 10§†‡ <0.001
Hemoglobin (mmol/L) 8.8 ± 0.7 8.7 ± 0.7 8.8 ± 0.7 9.0 ± 0.8§† 0.003
Creatinine (µmol/L) 75.0 ± 14.1 73.8 ± 14.1 76.0 ± 16.2 78.4 ± 14.7 0.051
ALT (IU/L) 23 ± 10 27 ± 12 25 ± 9 31 ± 14§†‡ <0.001
AST (IU/L) 22 ± 6 22 ± 7 23 ± 6 25 ± 8§† 0.002
Use of statins (%) 9.7 6.6 11.5 13.5 0.293
Use of antihypertensives (%) 17.2 15.7 14.8 28.2 0.022
Family history of diabetes (%) 24.7 21.5 18.3 25.2 0.685
Glucose status (%) <0.001
NGT 78.4 71.1 75.4 62.2
IFG 6.2 0.8 11.5 2.6
IGT 7.0 18.2 6.6 16.7
Combined IFG/IGT 1.8 1.7 6.6 7.7
T2DM 6.6 8.3 0.0 10.9
Employment status (%) 0.429
Paid job 44.6 49.2 43.3 36.8
Retired 39.7 37.5 36.7 42.6
Other 15.6 13.3 20.0 17.0
Education level (%) 0.257
Low 17.9 11.8 25.0 21.7
Intermediate 31.8 39.5 28.3 30.9
High 50.2 48.7 46.7 47.4
Differences between tissue-specific IR groups were assessed using one-way ANOVA with Bonferroni post-hoc pairwise comparisons for numerical data (mean± SD), and using Fisher’s
exact test for categorial data (%).
§Significantly different from No MIR/LIR (p < 0.05).
†Significantly different from MIR (p < 0.05).
‡Significantly different from LIR (p < 0.05).
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; ALT, alanine transaminase; AST, aspartate aminotransferase; NGT, normal glucose tolerant; IFG,
impaired fasting glucose; IGT, impaired glucose tolerance; T2DM, type 2 diabetes mellitus.
of energy from saturated fat was highest in the combined
MIR/LIR group, although only statistically significantly
higher compared to the MIR group. Other components
of macronutrient composition of habitual dietary intake,
expressed as en%, did not differ between the IR phenotypes
when adjusted for sex. Alcohol consumption was lower in
the combined MIR/LIR group compared to No MIR/LIR
(overall p= 0.011).
DISCUSSION
The purpose of the present article was to describe the study
design of the PERSON study and to present preliminary
screening results. In the PERSON study, individuals are classified
based on IR phenotype at baseline, and randomized to follow
a hypothesized optimal or suboptimal diet according to their
metabolic phenotype. This study is one of the first randomized
double-blind controlled trials in the field of precision nutrition
to investigate whether a dietary intervention based on tissue-
specific insulin sensitivity improves metabolic health to a greater
extent compared to a hypothesized suboptimal diet.
Dietary Intervention
Both intervention diets prescribed in this study are largely in
line with the Dutch dietary guidelines of the Health Council
of the Netherlands (36). Data from the FFQ indicated that the
habitual dietary intake of our study population did not meet these
guidelines. In particular, average fiber intake (2.6 g/MJ) was well
below the recommended 3.4 g/MJ, and lower than the targeted
fiber intake of 3 g/MJ and 4 g/MJ in the HMUFA and LFHP
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FIGURE 6 | Plasma glucose (A–C) and insulin (D–F) concentrations during an oral glucose tolerance test according to insulin resistance phenotype. (A,D): data are
geometric means with 95% confidence intervals; significant differences for MIR vs. LIR as analyzed using estimated marginal means from linear mixed-effects models
with adjustment for sex and Bonferroni post-hoc pairwise comparisons are denoted with *(p < 0.05) or ***(p < 0.001). (B,C,E,F): data are adjusted geometric means
with 95% confidence intervals. Different letters (a, b, c, d) indicate significant differences (p < 0.05) between IR phenotypes, as tested using ANCOVA with adjustment
for sex and Bonferroni post-hoc pairwise comparisons.
interventions diets, respectively. In addition, average intake of
calories from saturated fat (14 en%) exceeded the <10 en% that
is recommended. In our study, prescribed intake of saturated
fat and mono- and disaccharides, which is similar between the
two interventions diets, is lower than the average habitual intake.
Therefore, we expect that on average, participants will benefit
from both dietary interventions, regardless of their IR phenotype.
Nevertheless, we hypothesize to find greater improvements in
glucose homeostasis and related outcomes in study participants
that follow the anticipated optimal compared to suboptimal diet.
The hypothesis that dietary macronutrient composition
interacts with tissue-specific IR is supported by findings from
recent studies. A post-hoc analysis of the CORDIOPREV-
DIAB study indicated that individuals with predominant MIR
had a greater improvement in disposition index on a 2-year
Mediterranean diet, while individuals with predominant LIR
benefitted more from a diet high in complex carbohydrates and
low in fat (18). In addition, individuals with LIR have been shown
to have a more detrimental fasting plasma lipid profile (13) and
impaired postprandial lipoprotein metabolism following high-fat
meals (70) compared to individuals with MIR, which suggests
that a low-fat diet may be especially beneficial for individuals with
LIR (71). Furthermore, findings from other studies indicate that
a high protein diet and high fiber diet may have beneficial effects
for individuals with LIR, as both high protein and high fiber diets
have been shown to successfully reduce liver fat content (72–75).
Liver fat accumulation has been related to decreased suppression
of hepatic glucose production in some studies (74, 76), linking
liver fat to LIR, although the cause-effect relationship remains to
be established. Moreover, increased fiber intake has been shown
to improve insulin sensitivity in individuals with IFG but not
IGT (77). IFG is characterizedmainly by impaired hepatic insulin
sensitivity (78, 79), which is in line with observations in our study
that individuals with IFG are most often characterized as LIR.
In addition, dietary fat quality may impact skeletal muscle
lipid handling. In an acute study, meals high in saturated
fat resulted in increased postprandial skeletal muscle fatty
TAG extraction and/or reduced intramyocellular lipid turnover
compared to meals high in unsaturated FAs in insulin resistant
individuals, which was accompanied by a lower postprandial
insulin sensitivity (80). Taken together, a “one-size-fits-all”
approach with population-wide dietary guidelines may not be
optimal for metabolic health for all individuals. A diet targeting
tissue-specific IR is expected to increase the effectiveness
of dietary interventions with respect to improvements in
glucose homeostasis.
Changes in macronutrient composition within the context of
an isocaloric diet can improve risk factors for cardiometabolic
diseases, independent of weight loss (81). The two diets
implemented in the PERSON study differ in macronutrient
composition, and are bothmatched to the participants’ individual
energy requirements in order to maintain weight stability during
the dietary intervention. Throughout the study, participants’
body weight is monitored weekly, and adjustments in absolute
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FIGURE 7 | HOMA-IR (A), HOMA-β (B), Matsuda index (C), disposition index (D), muscle insulin sensitivity index (E), and hepatic insulin resistance index (F)
according to insulin resistance (IR) phenotype. Data are adjusted geometric means with 95% confidence intervals. Different letters (a, b, c, d) indicate significant
differences (p < 0.05) between IR phenotypes, as tested using ANCOVA with adjustment for sex and Bonferroni post-hoc pairwise comparisons.
TABLE 3 | Habitual dietary intake from FFQ according to insulin resistance phenotype.
No MIR/LIR MIR LIR Combined MIR/LIR P-value
(n = 180) (n = 98) (n = 53) (n = 130)
Energy (MJ)a 9.5 ± 1.0 8.8 ± 1.0 9.5 ± 1.0 9.6 ± 1.0 0.062
Fat (en%) 37.6 ± 0.4 36.8 ± 0.6 37.3 ± 0.8 38.5 ± 0.5 0.127
Monounsaturated fat 13.5 ± 0.2 13.1 ± 0.2 13.3 ± 0.3 13.6 ± 0.2 0.551
Polyunsaturated fat 7.2 ± 0.1 7.1 ± 0.2 7.1 ± 0.2 7.1 ± 0.1 0.946
Saturated fat 13.8 ± 0.2 13.4 ± 0.3 13.8 ± 0.4 14.5 ± 0.3† 0.024
Carbohydrates (en%) 41.1 ± 0.5 42.6 ± 0.6 42.1 ± 0.8 40.9 ± 0.5 0.137
Mono- and disaccharides 19.0 ± 0.4 20.0 ± 0.6 19.8 ± 0.8 18.4 ± 0.5 0.150
Polysaccharides 22.1 ± 0.3 22.6 ± 0.4 22.3 ± 0.6 22.5 ± 0.4 0.748
Fiber (g/MJ) 2.6 ± 0.0 2.6 ± 0.1 2.6 ± 0.1 2.5 ± 0.1 0.538
Alcohol (en%)b 2.3 ± 0.1 1.8 ± 0.1 2.0 ± 0.1 1.6 ± 0.1§ 0.011
Protein (en%) 15.7 ± 0.2 15.7 ± 0.2 15.2 ± 0.3 15.8 ± 0.2 0.401
Animal-based, % of total 58.4 ± 0.7 58.4 ± 1.0 57.1 ± 1.3 59.5 ± 0.8 0.475
Plant-based, % of total 41.6 ± 0.7 41.6 ± 1.0 42.9 ± 1.3 40.5 ± 0.8 0.481
Differences between tissue-specific IR groups were assessed using ANCOVA with adjustment for sex and with Bonferroni post-hoc pairwise comparisons (adjusted mean ± SE).
aData were logtransformed to improve normality and reported as geometric means.
bA constant was added before logtransformation to eliminate zero values.
§Significantly different from No MIR/LIR (p < 0.05).
†Significantly different from MIR (p < 0.05).
FFQ, Food Frequency Questionnaire; MJ, megajoule; en%, energy percentage of total energy intake.
energy intake, but not diet composition, are made if needed to
maintain body weight. We provide key food products, perform
unannounced food records, and conduct weekly check-ins
with skilled dieticians and researchers, together increasing the
incentive to adhere to the diet and the possibility to assess
dietary compliance.
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Extensive and Detailed Phenotyping
A strength of the PERSON-study is the extensive and detailed
phenotyping of the study participants before and after the
dietary intervention. This allows us to comprehensively study the
metabolic underpinnings of the metabolic response to the dietary
intervention. Next to performing highly standardized metabolic
phenotyping in a laboratory setting, we also collect data in
free-living conditions. Furthermore, in a subgroup of the study
population several additional measurements such as the gold-
standard hyperinsulinemic-euglycemic clamp are performed,
which allows us to investigate the mechanisms involved in the
pathophysiology of tissue-specific IR as well as how these may be
affected by the dietary intervention.
Next to detailed metabolic phenotyping, we also collect data
on mood, perceived well-being, food preferences and cognitive
function. There are indications that blood glucose levels may
be an important determinant of mood and cognitive function
(19, 21, 82, 83). Additionally, gut microbial profile, which
can be modulated by dietary intake, is linked to cognitive
function and mood via the gut-brain axis (84, 85). Hence,
by improving glucose homeostasis and metabolic health with
a dietary intervention, individuals may also experience short-
term benefits related to mental and emotional well-being and
performance. Such directly perceivable benefits are expected to
motivate individuals to better adhere to dietary advice.
In addition, the large amount of collected data will allow for
the application of computational techniques to elucidate
the inter-individual differences in glucose homeostasis
and derive new functional insights. Both mechanistic and
data-driven computational modeling approaches have
been employed to expand on the physiological properties
underlying meal responses (6, 7, 86). The frequently-
sampled time series of metabolites (e.g., glucose, insulin)
from the OGTT and continuous glucose monitoring will
be used to construct models of short-term postprandial
dynamics, facilitating the assessment of individuals’ capacity
to regulate glucose levels in response to a meal. The detailed
phenotypic information can be integrated using machine-
learning models to derive a comprehensive model of glucose
homeostasis. The data generated in the PERSON study will
enable such computational methods to progress the field of
precision nutrition.
Preliminary Screening Data
Tissue-specific or whole-body IR (either MIR, LIR or combined)
was prevalent in ∼60% of the population, which is similar to
the reported prevalence of 65% in DMS (16). The prevalence
of LIR in this study was lower as compared to DMS (11
vs. 17%, respectively). This can possibly be partly explained
by the higher proportion of women in the PERSON study
compared to DMS (59 vs. 44%, respectively), since LIR is
less prevalent in women than men. Sexual dimorphism in
glucose homeostasis and IR is well-recognized and has been
linked to differences in relation to hormonal status, lipid
handling and inflammatory profile (87), but does require
further investigation. These data emphasize that future analyses
within the PERSON study should also take sex-specific effects
into account.
As expected based on the formulas used to classify MIR and
LIR, our preliminary screening data confirmed that both MIR
and LIR are related to worse glucose homeostasis compared
to individuals without MIR or LIR, in line with observations
from DiOGenes and DMS (16, 22). Interestingly, however, the
majority of individuals with MIR and LIR (71 – 75%) were
classified as normal glucose tolerant. Classical cutoff values only
including plasma glucose levels may fail to detect important
metabolic impairments related to insulin action, especially in
early stages of disease development, while these disturbances
are well-known to be highly predictive for the development of
cardiometabolic diseases later in life (88, 89). Identification of
metabolic impairments at an early stage before the onset of
dysglycemia creates an important window of opportunity to use
lifestyle interventions such as dietary modulation in order to
delay or prevent further glycemic deterioration and progression
to cardiometabolic disease.
CONCLUSION
The PERSON study is one of the first double-blind, randomized
trials in the field of precision nutrition to investigate the effects of
a more personalized dietary intervention based on tissue-specific
insulin resistance phenotype, on metabolic health outcomes at
the functional and molecular level, mental performance and
perceived well-being. The high prevalence of tissue-specific IR
in adults with overweight and obesity highlights the relevance
of investigating the effects of targeted dietary approaches
in order to define more optimal diets to improve glucose
homeostasis, thereby preventing or delaying the development
of cardiometabolic diseases. The PERSON study is expected to
contribute knowledge on the effectiveness of targeted nutritional
strategies to the emerging field of precision nutrition and enhance
the understanding of the complex etiology of generalized and
tissue-specific IR.
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